PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products ...
ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m ...
PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the successful restarting of the BR2 research reactor in Belgium on 20 December ...
-- Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the ...
Curium Pharma, the CapVest Partners-backed nuclear medicine imaging company, is poised to field first round bids early next week, people with knowledge of the matter told PE Hub. A process formally ...
PARIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate ...
The proposed acquisition of Eczacibasi-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium's existing network in geographies ...
PETTEN, The Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which ...
Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback